Research Analysts Offer Predictions for CMPX FY2028 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share estimates for Compass Therapeutics in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.94 for the year, up from their previous estimate of $0.85. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share.

Other equities analysts have also recently issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a report on Wednesday, August 7th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a report on Monday, September 16th.

Compass Therapeutics Trading Down 5.9 %

CMPX opened at $1.59 on Thursday. The stock has a 50-day moving average price of $1.75 and a 200-day moving average price of $1.42. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.34. The stock has a market capitalization of $218.77 million, a P/E ratio of -4.47 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rovin Capital UT ADV bought a new position in shares of Compass Therapeutics in the 3rd quarter worth approximately $25,000. Intech Investment Management LLC bought a new position in shares of Compass Therapeutics in the 3rd quarter worth approximately $30,000. SG Americas Securities LLC raised its position in shares of Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after acquiring an additional 5,515 shares in the last quarter. Bleakley Financial Group LLC bought a new position in shares of Compass Therapeutics in the 1st quarter worth approximately $80,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Compass Therapeutics in the 2nd quarter worth approximately $41,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.